TTrialPathMatch Me to Trials
← Back to trials
RecruitingRefractory Multiple MyelomaRelapsed Multiple Myeloma

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Eligible age

18–75 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.

Sponsor: Benjamin T Diamond, MD

You may qualify if…

  • ✓ 1. Patients with histologically confirmed MM with progressive disease according to the IMWG criteria 47 during or within 60 days of their last regimen who have received 1-3 lines of prior therapy (inclusive of a lenalidomide-containing regimen) and have measurable disease within 4 weeks of enrollment based on one of the following:
  • ✓ Serum monoclonal protein ≥ 1.0 g/dL
  • ✓ Urine monoclonal protein ≥ 200 mg/24 hour
  • ✓ Involved serum immunoglobulin free light chains (FLC) ≥ 10 mg/dL AND abnormal kappa/lambda ratio.
  • ✓ Note: Because the primary endpoint is MRD-negativity rate, per the discretion of the Principal Investigator (PI), patients without measurable disease (e.g., M-spike \< 1.0 g/dL) may also be enrolled in line with the IMWG MM response criteria 47.
  • ✓ 2. Prior treatment with cluster of differentiation 38 (CD38) -directed therapy is permitted only if all the following are fulfilled:
  • ✓ Best response achieved during CD38-directed therapy was ≥ PR.
  • ✓ Patient did not progress while receiving CD38-directed therapy or within 60 days of last dose of therapy.

You may not qualify if…

  • ✕ 1. Patients receiving concurrent systemic treatment for MM with the following exceptions:
  • ✕ Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted.
  • ✕ Patients may receive kyphoplasty/vertebroplasty for symptomatic vertebral compression fractures.
  • ✕ Bone targeting agents are permitted.
  • ✕ Concurrent or prior treatment with corticosteroids for indications other than MM is permitted.
  • ✕ Focal radiation therapy within 14 days prior to randomization with the exception of palliative radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma.
  • ✕ Prior MM treatments must be concluded with a washout period of 2 weeks from last dose.
  • ✕ 2. Patients who are refractory to an anti-CD38-directed regimen:

Where it's recruiting

Florida

Miami

Source: ClinicalTrials.gov · NCT05896228 · last updated 2026-03-11

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in · TrialPath